CN113527470B - 抗前-s1 hbv抗体 - Google Patents

抗前-s1 hbv抗体 Download PDF

Info

Publication number
CN113527470B
CN113527470B CN202110657776.0A CN202110657776A CN113527470B CN 113527470 B CN113527470 B CN 113527470B CN 202110657776 A CN202110657776 A CN 202110657776A CN 113527470 B CN113527470 B CN 113527470B
Authority
CN
China
Prior art keywords
ser
seq
gly
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202110657776.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN113527470A (zh
Inventor
隋建华
李丹
李文辉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Institute of Biological Sciences Beijin
Original Assignee
National Institute of Biological Sciences Beijin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Institute of Biological Sciences Beijin filed Critical National Institute of Biological Sciences Beijin
Priority to CN202110657776.0A priority Critical patent/CN113527470B/zh
Publication of CN113527470A publication Critical patent/CN113527470A/zh
Application granted granted Critical
Publication of CN113527470B publication Critical patent/CN113527470B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—DNA viruses
    • C07K16/082—Hepadnaviridae (F), e.g. hepatitis B virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN202110657776.0A 2015-05-22 2016-05-23 抗前-s1 hbv抗体 Active CN113527470B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110657776.0A CN113527470B (zh) 2015-05-22 2016-05-23 抗前-s1 hbv抗体

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2015079534 2015-05-22
CNPCT/CN2015/079534 2015-05-22
CN202110657776.0A CN113527470B (zh) 2015-05-22 2016-05-23 抗前-s1 hbv抗体
CN201680029377.7A CN107614525B (zh) 2015-05-22 2016-05-23 抗前-s1 hbv抗体
PCT/CN2016/082985 WO2016188386A1 (en) 2015-05-22 2016-05-23 Anti-Pre-S1 HBV Antibodies

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201680029377.7A Division CN107614525B (zh) 2015-05-22 2016-05-23 抗前-s1 hbv抗体

Publications (2)

Publication Number Publication Date
CN113527470A CN113527470A (zh) 2021-10-22
CN113527470B true CN113527470B (zh) 2023-08-25

Family

ID=57392535

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202110657776.0A Active CN113527470B (zh) 2015-05-22 2016-05-23 抗前-s1 hbv抗体
CN201680029377.7A Active CN107614525B (zh) 2015-05-22 2016-05-23 抗前-s1 hbv抗体
CN202310981391.9A Pending CN117247944A (zh) 2015-05-22 2016-05-23 抗前-s1 hbv抗体

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN201680029377.7A Active CN107614525B (zh) 2015-05-22 2016-05-23 抗前-s1 hbv抗体
CN202310981391.9A Pending CN117247944A (zh) 2015-05-22 2016-05-23 抗前-s1 hbv抗体

Country Status (10)

Country Link
US (3) US20180094047A1 (https=)
EP (2) EP3978521A1 (https=)
JP (2) JP6820278B2 (https=)
KR (1) KR102770671B1 (https=)
CN (3) CN113527470B (https=)
ES (1) ES2896275T3 (https=)
HK (1) HK1243429A1 (https=)
MA (1) MA42137A (https=)
RU (1) RU2739955C2 (https=)
WO (1) WO2016188386A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113527470B (zh) 2015-05-22 2023-08-25 华辉安健（北京）生物科技有限公司 抗前-s1 hbv抗体
US11459393B2 (en) 2018-04-17 2022-10-04 Celldex Therapeutics, Inc. Anti-CD27 and anti-PD-L1 antibodies and bispecific constructs
JP7454855B2 (ja) * 2018-12-21 2024-03-25 国立大学法人広島大学 抗ｐｒｅＳ１抗体およびその用途
CA3145057A1 (en) 2019-07-20 2021-01-28 Wenhui Li A method of treating hbv infection by using anti-pre-s1 hbv antibodies
KR102680147B1 (ko) * 2021-06-15 2024-07-03 에이피트바이오 주식회사 B형 간염바이러스 preS1항원의 간세포 수용체 결합부위에 특이적으로 결합하는 인간 항체 및 이의 용도
US20240391979A1 (en) * 2021-09-13 2024-11-28 Achelois Biopharma, Inc. Hepatitis b virus antivirus (hbv-antivirus) compositions and methods of use
CN116568808A (zh) * 2021-10-19 2023-08-08 北京三诺佳邑生物技术有限责任公司 特异性结合乙型肝炎病毒表面抗原pre-S1的抗体及其应用
CN114685663B (zh) * 2022-04-07 2023-09-08 西南大学 一种抗胆固醇依赖性细胞溶素的抗体及其应用
CN117304308A (zh) * 2022-06-20 2023-12-29 华辉安健（北京）生物科技有限公司 抗乙型肝炎病毒的抗体及其制备和应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1733798A (zh) * 2005-08-12 2006-02-15 上海汐群生物科技有限公司 乙型肝炎病毒表面l蛋白相关肽
US7115723B1 (en) * 1998-11-19 2006-10-03 Korea Institute Of Science And Technology Humanized antibody specific for surface antigen pre-S1 of HBV and preparation method thereof
US7601351B1 (en) * 2002-06-26 2009-10-13 Human Genome Sciences, Inc. Antibodies against protective antigen
WO2013159243A1 (en) * 2012-04-25 2013-10-31 National Institute Of Biological Sciences, Beijing Compositions and uses of functional receptor for hbv/hdv virus

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
CA2041772A1 (en) * 1990-05-11 1991-11-12 Larry T. Mimms Monoclonal antibodies to pres2 and pres1 polypeptide of the hepatitis b viral envelope
JP2002502222A (ja) * 1992-11-06 2002-01-22 ノバーティス アクチエンゲゼルシャフト Ｂ型肝炎表面抗原に対して活性なヒトモノクローナル抗体の生産
CN1216914C (zh) * 2000-05-17 2005-08-31 韩国科学技术研究院 对hbv表面抗原pre－s1具有特异性的人源化抗体
KR100423614B1 (ko) * 2001-05-16 2004-03-22 주식회사유한양행 비형간염바이러스의 에스-표면항원을 인식하는단일클론항체의 가변영역 및 이를 코딩하는 유전자
EP1281761A1 (en) * 2001-07-27 2003-02-05 Institut National De La Sante Et De La Recherche Medicale (Inserm) Hepatitis B virus pre-S1 derived synthetic polypeptides and their use thereof.
WO2011045079A1 (en) * 2009-10-15 2011-04-21 Intercell Ag Hepatitis b virus specific human antibodies
CN113527470B (zh) 2015-05-22 2023-08-25 华辉安健（北京）生物科技有限公司 抗前-s1 hbv抗体

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7115723B1 (en) * 1998-11-19 2006-10-03 Korea Institute Of Science And Technology Humanized antibody specific for surface antigen pre-S1 of HBV and preparation method thereof
US7601351B1 (en) * 2002-06-26 2009-10-13 Human Genome Sciences, Inc. Antibodies against protective antigen
CN1733798A (zh) * 2005-08-12 2006-02-15 上海汐群生物科技有限公司 乙型肝炎病毒表面l蛋白相关肽
WO2013159243A1 (en) * 2012-04-25 2013-10-31 National Institute Of Biological Sciences, Beijing Compositions and uses of functional receptor for hbv/hdv virus

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Fine mapping of virus-neutralizing epitopes on hepatitis B virus PreS1;C Y Maeng等;《Virology》;20000425;第270卷(第1期);9-16 *

Also Published As

Publication number Publication date
EP3298038B1 (en) 2021-08-04
CN117247944A (zh) 2023-12-19
JP2018519804A (ja) 2018-07-26
JP2020171311A (ja) 2020-10-22
US20200109186A1 (en) 2020-04-09
KR102770671B1 (ko) 2025-02-24
CN113527470A (zh) 2021-10-22
MA42137A (fr) 2021-04-07
EP3298038A1 (en) 2018-03-28
US20180148496A1 (en) 2018-05-31
EP3978521A1 (en) 2022-04-06
EP3298038A4 (en) 2019-04-24
WO2016188386A1 (en) 2016-12-01
CN107614525B (zh) 2021-07-06
US10544205B2 (en) 2020-01-28
JP7304320B2 (ja) 2023-07-06
US20220275060A9 (en) 2022-09-01
RU2017145085A3 (https=) 2020-01-23
CN107614525A (zh) 2018-01-19
US11485774B2 (en) 2022-11-01
RU2017145085A (ru) 2019-06-24
RU2739955C2 (ru) 2020-12-30
JP6820278B2 (ja) 2021-01-27
KR20180009780A (ko) 2018-01-29
ES2896275T3 (es) 2022-02-24
US20180094047A1 (en) 2018-04-05
HK1243429A1 (zh) 2018-07-13

Similar Documents

Publication Publication Date Title
CN113527470B (zh) 抗前-s1 hbv抗体
US20240417449A1 (en) Highly active agonistic cd4 binding site anti-hiv antibodies (haads) comprising modified cdrh2 regions that improve contact with gp120
CN112625136B (zh) 针对冠状病毒具有中和活性的双特异性抗体及其用途
JP2022002524A (ja) ポリオーマウイルス中和抗体
US9541004B2 (en) Antagonist antibodies against EphB3
CN113508139B (zh) 结合人lag-3的抗体、其制备方法和用途
JP2018148915A (ja) 抗ｖａｓａ抗体、ならびにその産生法および使用法
JP2014526886A (ja) マクロファージ遊走阻止因子（ｍｉｆ）とｄ−ドーパクロームトートメラーゼ（ｄ−ｄｔ）に交差反応性がある抗体
CN107922939B (zh) 中和全部种类埃博拉病毒的感染性的单克隆抗体
CN114685653A (zh) 抗新冠病毒受体结合区域表位中和抗体及其应用
KR20220087457A (ko) Lif에 특이적인 결합 분자 및 이의 용도
HK40095854A (zh) 抗前-s1 hbv抗体
WO2023046039A1 (zh) 抗SARS-CoV-2 E484Q刺突蛋白的单克隆抗体及其应用
WO2014006230A1 (en) Il-20 epitopes and il-20 ligands
CN115515977A (zh) 针对areg的抗体及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant